Search research articles
Contact Us
Filters
Showing results (261-270 of 276) with videos related to
Page
of 28
Sort By:
Science (New York, N.Y.)
|
December 28, 2020
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
Mads Delbo Larsen, Erik L de Graaf, Myrthe E Sonneveld, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 28, 2024
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Niels J M Verstegen, Ruth R Hagen, Christine Kreher, et al.
RMD Open
|
October 7, 2024
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID
Laura Y L Kummer, Laura Fernández Blanco, Christine Kreher, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Ebiomedicine
|
December 18, 2022
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
Julie Van Coillie, Tamas Pongracz, Johann Rahmöller, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
Science Translational Medicine
|
May 12, 2021
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages
Willianne Hoepel, Hung-Jen Chen, Chiara E Geyer, et al.
The Journal of Allergy and Clinical Immunology
|
January 30, 2023
Differences in IgG autoantibody Fab glycosylation across autoimmune diseases
Jana Koers, Rocco Sciarrillo, Ninotska I L Derksen, et al.
BMC Medicine
|
March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
Luuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity
|
January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
Koos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 276) with videos related to
Sort By:
Page
of 28
Science (New York, N.Y.)
|
December 28, 2020
Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity
Mads Delbo Larsen, Erik L de Graaf, Myrthe E Sonneveld, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 28, 2024
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
Niels J M Verstegen, Ruth R Hagen, Christine Kreher, et al.
RMD Open
|
October 7, 2024
Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID
Laura Y L Kummer, Laura Fernández Blanco, Christine Kreher, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Liza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
Ebiomedicine
|
December 18, 2022
The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
Julie Van Coillie, Tamas Pongracz, Johann Rahmöller, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 14, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)
Alyssa A Toorop, Zoë Ygj van Lierop, Liza My Gelissen, et al.
Science Translational Medicine
|
May 12, 2021
High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages
Willianne Hoepel, Hung-Jen Chen, Chiara E Geyer, et al.
The Journal of Allergy and Clinical Immunology
|
January 30, 2023
Differences in IgG autoantibody Fab glycosylation across autoimmune diseases
Jana Koers, Rocco Sciarrillo, Ninotska I L Derksen, et al.
BMC Medicine
|
March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
Luuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Journal of Autoimmunity
|
January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
Koos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
Page
of 28